381226-39-7

Basic information

• Product Name: C₂₁H₃₆O₃Si₂
• Synonyms: C₂₁H₃₆O₃Si₂
• CAS NO: 381226-39-7
• Molecular Weight: 392.686
• Mol File: 381226-39-7.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: C₂₁H₃₆O₃Si₂(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₁H₃₆O₃Si₂(381226-39-7)
• EPA Substance Registry System: C₂₁H₃₆O₃Si₂(381226-39-7)

Safety Data

• Hazardous Substances Data: 381226-39-7(Hazardous Substances Data)

Upstream product

• 7400-08-0 p-Coumaric Acid 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 141222-05-1 3-<4-<<(1',1'-dimethylethyl)dimethylsilyl>oxy>phenyl>prop-2-enyl bromide 
• 1026806-53-0 1-[4-(2-benzhydryloxy-ethyl)-piperazin-1-yl]-3-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-propenone 
• 1026635-75-5 (E)-1-[4-(2-Benzhydryloxy-ethyl)-piperazin-1-yl]-3-(4-hydroxy-phenyl)-propenone 
• 854737-67-0 3-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-acrylic acid 3-[3,4-bis-(tert-butyl-dimethyl-silanyloxy)-phenyl]-2-oxo-propyl ester 
• 854737-63-6 3-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-acrylic acid 3-[4-(tert-butyl-dimethyl-silanyloxy)-3-methoxy-phenyl]-2-oxo-propyl ester 
• 141222-28-8 (E)-3-(4'-((tert-butyldimethylsilyl)oxy)phenyl)acrylic acid 
• 125872-66-4 (E)-3-(4-((tert-butyldimethylsilyl)oxy)phenyl)prop-2-en-1-ol 

Relevant articles and documents

Design, synthesis and evaluation of cinnamic acid ester derivatives as mushroom tyrosinase inhibitors

Tyrosinase is a key enzyme in melanin biosynthesis, and is also involved in the enzymatic browning of plant-derived foods. Tyrosinase inhibitors are very important in medicine, cosmetics and agriculture. In order to develop more active and safer tyrosinase inhibitors, an efficient approach is to modify natural product scaffolds. In this work, two series of novel tyrosinase inhibitors were designed and synthesized by the esterification of cinnamic acid derivatives with paeonol or thymol. Their inhibitory effects on mushroom tyrosinase were evaluated. Most of these compounds (IC50: 2.0 to 163.8 μM) are found to be better inhibitors than their parent compounds (IC50: 121.4 to 5925.0 μM). Among them, (E)-2-acetyl-5-methoxyphenyl-3-(4-hydroxyphenyl)acrylate (5a), (E)-2-acetyl-5-methoxyphenyl-3-(4-methoxyphenyl)acrylate (5g) and (E)-2-isopropyl-5-methylphenyl-3-(4-hydroxyphenyl)acrylate (6a) showed strong inhibitory activities; the IC50 values were 2.0 μM, 8.3 μM and 10.6 μM, respectively, compared to the positive control, kojic acid (IC50: 32.2 μM). Analysis of the inhibition mechanism of 5a, 5g and 6a demonstrated that their inhibitory effects on tyrosinase are reversible. The inhibition kinetics, analyzed by Lineweaver-Burk plots, revealed that 5a acts as a non-competitive inhibitor while 5g and 6a are mixed-type inhibitors. Furthermore, docking experiments were carried out to study the interactions between 6a and mushroom tyrosinase.

Total synthesis of cimiracemate B and analogs

The synthesis of the biologically active cimiracemate B and some analogs is described. The key step of the synthesis is a coupling between a bromoketone and a cinnamic acid derivative.

Oxygenated analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1- [2- [bis (4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as potential extended-action cocaine-abuse therapeutic agents

An investigation into the preparation of potential extended-release cocaine-abuse therapeutic agents afforded a series of compounds related to 1- [2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine (1a) and 1-[2-[bis(4- fluorophenyl)methoxy]ethyl]-4-(